But the data did not really support this hypothesis since the median delay between stroke and treatment was 174 minutes and 86% of the patients in the intensive insulin regimen had a glycemic value under the target (<7 mmol/l) four hours after treatment initiation. The gene discussed is INS; the disease is Stroke.